. home.aspx



Geisinger officials explain the business case for making DNA sequencing 'routine'

May 08, 2018 / Tina Reed

It wasn't that long ago that the cost of DNA sequencing was measured in the millions of dollars. Even a few years ago, when the cost fell closer to a few thousand dollars, it was largely used for research purposes or reactively as a tool for patients who'd already fallen ill. Now, Geisinger President and CEO David Feinberg, M.D., said the time and cost is finally right to make whole exome sequencing a "routine" part of screening for patient diseases.